Deep multiplexed 50-marker imaging of circulating tumor cells expands actionable biomarker profiling for precision oncology
Timothy J. Mann(UNSW Sydney), John G. Lock(UNSW Sydney), Ye Zheng(Fred Hutch Cancer Center), Tanzila Khan(Ingham Institute), Felix V Kohane(UNSW Sydney), Daniel Neumann(UNSW Sydney), Tara L. Roberts(Camden and Campbelltown Hospitals), Therese M. Becker(Liverpool Hospital), Yafeng Ma(Camden and Campbelltown Hospitals), Wei Chua(Liverpool Hospital), Udit Nindra(Camden and Campbelltown Hospitals), Alexander C. James(UNSW Sydney), Fatemeh Vafaee(The University of Sydney), Ihuan Gunawan(UNSW Sydney), Tim H-M. Huang(The University of Sydney), Paul de Souza(St. George Hospital)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507